BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk. Significance: To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections. See related commentary by Garfall and Stadtmauer, p. 427 . This article is featured in Selected Articles from This Issue, p. 419
1 July 2025 in Advances in Methods and Practices in Psychological Science
Concerns for the replicability, reliability, and generalizability of MRI and functional MRI (fMRI) research have led to debates over the contributions of sample size, open-science practices, and recruitment methods, particularly in the psychological sciences. Key to understanding the state of a science is an assessment of reporting practices. In this structured review, we evaluated select reporting practices across three domains: (a) demographic (e.g., age), (b) methodological (e.g., inclusion/exclusion criteria), and (c) open science and generalizability (e.g., preregistration, target-population identification). Included were 919 published MRI and fMRI studies from 2019 in nine top-ranked journals. Reporting across domains was infrequent; participant racial-ethnic identity (14.8%), reasons for missing imaging data (31.2%), and identification of a target population (19.4%) were particularly low. Reporting likelihood varied by study characteristics (e.g., journal) and was correlated across domains. Finally, study sample size but not reporting frequency was positively associated with 2-year citation counts. Results call for recentering transparency in reporting practices in MRI and fMRI studies, with direct implications for study generalizability.
Supplementary Table S1: Description of all grade 3-5 infections. Supplementary Table S2: Infection rates per time period from start of bispecific antibody, divided by presumed microbiology. Rates are presented as infections per patient-year (95% confidence intervals). Supplementary table S3: Univariate logistic regression analysis of baseline risk factors for grade 3-5 infections among responders.
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple myeloma; however, serious infections have emerged as important toxicities. In this retrospective study, we characterized all infections and their risk factors, and evaluated the impact of infection prophylaxis in patients treated with BCMA-targeted BiAbs. Among 37 patients, 15 (41%) experienced a grade 3–5 infection, with two infection-related deaths during deep remissions. Most (84%) infections occurred during disease remissions. The cumulative probability of grade 3–5 infection increased over time with no plateau. Among responders (n = 26), profound hypogammaglobulinemia occurred in 100% and continued throughout the entire duration of treatment. During periods when patients were receiving intravenous immunoglobulin (IVIg), the rate of grade 3–5 infections was 90% lower than during observation (incidence rate ratio, 0.10; 95% confidence interval, 0.01–0.80; P = 0.0307). No other risk factors for infection were identified. This study demonstrates that profound hypogammaglobulinemia is universal with BCMA-targeted BiAbs, with intravenous immunoglobulin potentially abrogating most of the infection risk.Significance:To the best of our knowledge, this is the first study to comprehensively analyze risk factors and mitigation strategies to prevent infections in myeloma patients receiving anti-BCMA bispecific antibodies. Profound and prolonged hypogammaglobulinemia was universal among responders, while immunoglobulin replacement was associated with 90% lower rates of grade 3–5 infections.See related commentary by Garfall and Stadtmauer, p. 427.This article is featured in Selected Articles from This Issue, p. 419